Lactoferrin blocks orthopoxvirus entry via heparan sulphate and regulates host antiviral pathways

Current antiviral therapies for orthopoxviruses face critical challenges, including limited efficacy and significant toxicity, which impede outbreak containment and clinical management. Here, we identify lactoferrin as a potent antiviral agent against multiple orthopoxvirus strains. Combination admi...

Full description

Bibliographic Details
Published in:Emerging Microbes and Infections
Main Authors: Lili Tian, Hongbo Qin, Sha Li, Mengjie Zhang, Lu Zhuang, Bixia Hong, Ke Liu, Maochen Li, Siyue Li, Yaxin Wang, Lihua Song, Yang Liu, Yun Wang, Huiyu Liu, Yigang Tong, Huahao Fan
Format: Article
Language:English
Published: Taylor & Francis Group 2026-12-01
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/22221751.2026.2631205
_version_ 1875639674740932608
author Lili Tian
Hongbo Qin
Sha Li
Mengjie Zhang
Lu Zhuang
Bixia Hong
Ke Liu
Maochen Li
Siyue Li
Yaxin Wang
Lihua Song
Yang Liu
Yun Wang
Huiyu Liu
Yigang Tong
Huahao Fan
author_facet Lili Tian
Hongbo Qin
Sha Li
Mengjie Zhang
Lu Zhuang
Bixia Hong
Ke Liu
Maochen Li
Siyue Li
Yaxin Wang
Lihua Song
Yang Liu
Yun Wang
Huiyu Liu
Yigang Tong
Huahao Fan
author_sort Lili Tian
collection DOAJ
container_title Emerging Microbes and Infections
description Current antiviral therapies for orthopoxviruses face critical challenges, including limited efficacy and significant toxicity, which impede outbreak containment and clinical management. Here, we identify lactoferrin as a potent antiviral agent against multiple orthopoxvirus strains. Combination administration of lactoferrin with brincidofovir or tecovirimat demonstrated additive efficacy, suggesting a potential clinical strategy to reduce individual drug toxicity. Mechanistically, lactoferrin blocks viral entry by competitively binding to heparan sulphate proteoglycans (HSPGs). It also suppresses viral replication by regulating host antiviral pathways, including down-regulating cytokines and upregulating TGF-β-dependent antiviral signalling pathways. We identify TGFBI as a virus-responsive target regulated by lactoferrin. Lactoferrin treatment restores TGFBI expression and activates downstream MAPK/ERK and JAK2/STAT3 signalling cascades, leading to enhanced interferon production and interferon-stimulated gene (ISG) expression. In a murine vaccinia virus (VACV) infection model, lactoferrin treatment reduced lung viral loads and histological damage. These results underscore lactoferrin's distinctive dual antiviral mechanism and highlight its translational potential as a safe and cost-effective prophylactic or therapeutic agent. It is particularly beneficial for immunocompromised populations in resource-limited settings during orthopoxvirus outbreaks.
format Article
id doaj-art-cb86f00d7f3b42e392ff4e1e2f2feb3a
institution Directory of Open Access Journals
issn 2222-1751
language English
publishDate 2026-12-01
publisher Taylor & Francis Group
record_format Article
spelling doaj-art-cb86f00d7f3b42e392ff4e1e2f2feb3a2026-05-12T07:36:31ZengTaylor & Francis GroupEmerging Microbes and Infections2222-17512026-12-0115110.1080/22221751.2026.2631205Lactoferrin blocks orthopoxvirus entry via heparan sulphate and regulates host antiviral pathwaysLili Tian0Hongbo Qin1Sha Li2Mengjie Zhang3Lu Zhuang4Bixia Hong5Ke Liu6Maochen Li7Siyue Li8Yaxin Wang9Lihua Song10Yang Liu11Yun Wang12Huiyu Liu13Yigang Tong14Huahao Fan15College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, People’s Republic of ChinaCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, People’s Republic of ChinaWuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People’s Republic of ChinaInstitute of Infectious Diseases, Shenzhen Bay Laboratory, Shenzhen, People’s Republic of ChinaDepartment of Pediatric Medicine, the Seventh Medical Center of Chinese PLA General Hospital, Beijing, People’s Republic of ChinaCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, People’s Republic of ChinaCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, People’s Republic of ChinaCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, People’s Republic of ChinaCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, People’s Republic of ChinaSchool of Life Sciences, Tianjin University, Tianjin, People’s Republic of ChinaCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, People’s Republic of ChinaInstitute of Infectious Diseases, Shenzhen Bay Laboratory, Shenzhen, People’s Republic of ChinaWuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People’s Republic of ChinaCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, People’s Republic of ChinaCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, People’s Republic of ChinaCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, People’s Republic of ChinaCurrent antiviral therapies for orthopoxviruses face critical challenges, including limited efficacy and significant toxicity, which impede outbreak containment and clinical management. Here, we identify lactoferrin as a potent antiviral agent against multiple orthopoxvirus strains. Combination administration of lactoferrin with brincidofovir or tecovirimat demonstrated additive efficacy, suggesting a potential clinical strategy to reduce individual drug toxicity. Mechanistically, lactoferrin blocks viral entry by competitively binding to heparan sulphate proteoglycans (HSPGs). It also suppresses viral replication by regulating host antiviral pathways, including down-regulating cytokines and upregulating TGF-β-dependent antiviral signalling pathways. We identify TGFBI as a virus-responsive target regulated by lactoferrin. Lactoferrin treatment restores TGFBI expression and activates downstream MAPK/ERK and JAK2/STAT3 signalling cascades, leading to enhanced interferon production and interferon-stimulated gene (ISG) expression. In a murine vaccinia virus (VACV) infection model, lactoferrin treatment reduced lung viral loads and histological damage. These results underscore lactoferrin's distinctive dual antiviral mechanism and highlight its translational potential as a safe and cost-effective prophylactic or therapeutic agent. It is particularly beneficial for immunocompromised populations in resource-limited settings during orthopoxvirus outbreaks.https://www.tandfonline.com/doi/10.1080/22221751.2026.2631205Monkeypoxorthopoxvirusbreast milklactoferrinantiviral therapyheparan sulphate
spellingShingle Lili Tian
Hongbo Qin
Sha Li
Mengjie Zhang
Lu Zhuang
Bixia Hong
Ke Liu
Maochen Li
Siyue Li
Yaxin Wang
Lihua Song
Yang Liu
Yun Wang
Huiyu Liu
Yigang Tong
Huahao Fan
Lactoferrin blocks orthopoxvirus entry via heparan sulphate and regulates host antiviral pathways
Monkeypox
orthopoxvirus
breast milk
lactoferrin
antiviral therapy
heparan sulphate
title Lactoferrin blocks orthopoxvirus entry via heparan sulphate and regulates host antiviral pathways
title_full Lactoferrin blocks orthopoxvirus entry via heparan sulphate and regulates host antiviral pathways
title_fullStr Lactoferrin blocks orthopoxvirus entry via heparan sulphate and regulates host antiviral pathways
title_full_unstemmed Lactoferrin blocks orthopoxvirus entry via heparan sulphate and regulates host antiviral pathways
title_short Lactoferrin blocks orthopoxvirus entry via heparan sulphate and regulates host antiviral pathways
title_sort lactoferrin blocks orthopoxvirus entry via heparan sulphate and regulates host antiviral pathways
topic Monkeypox
orthopoxvirus
breast milk
lactoferrin
antiviral therapy
heparan sulphate
url https://www.tandfonline.com/doi/10.1080/22221751.2026.2631205
work_keys_str_mv AT lilitian lactoferrinblocksorthopoxvirusentryviaheparansulphateandregulateshostantiviralpathways
AT hongboqin lactoferrinblocksorthopoxvirusentryviaheparansulphateandregulateshostantiviralpathways
AT shali lactoferrinblocksorthopoxvirusentryviaheparansulphateandregulateshostantiviralpathways
AT mengjiezhang lactoferrinblocksorthopoxvirusentryviaheparansulphateandregulateshostantiviralpathways
AT luzhuang lactoferrinblocksorthopoxvirusentryviaheparansulphateandregulateshostantiviralpathways
AT bixiahong lactoferrinblocksorthopoxvirusentryviaheparansulphateandregulateshostantiviralpathways
AT keliu lactoferrinblocksorthopoxvirusentryviaheparansulphateandregulateshostantiviralpathways
AT maochenli lactoferrinblocksorthopoxvirusentryviaheparansulphateandregulateshostantiviralpathways
AT siyueli lactoferrinblocksorthopoxvirusentryviaheparansulphateandregulateshostantiviralpathways
AT yaxinwang lactoferrinblocksorthopoxvirusentryviaheparansulphateandregulateshostantiviralpathways
AT lihuasong lactoferrinblocksorthopoxvirusentryviaheparansulphateandregulateshostantiviralpathways
AT yangliu lactoferrinblocksorthopoxvirusentryviaheparansulphateandregulateshostantiviralpathways
AT yunwang lactoferrinblocksorthopoxvirusentryviaheparansulphateandregulateshostantiviralpathways
AT huiyuliu lactoferrinblocksorthopoxvirusentryviaheparansulphateandregulateshostantiviralpathways
AT yigangtong lactoferrinblocksorthopoxvirusentryviaheparansulphateandregulateshostantiviralpathways
AT huahaofan lactoferrinblocksorthopoxvirusentryviaheparansulphateandregulateshostantiviralpathways